Content about Gram positive bacteria

April 10, 2012

The Food and Drug Administration has approved a generic version of a drug for diarrhea made by Watson, the company said Tuesday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic version of a drug for diarrhea made by Watson, the company said Tuesday.

Watson announced the approval of vancomycin hydrochloride capsules in the 125-mg and 250-mg strengths. Vancomycin hydrochloride is used to treat diarrhea associated with Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.

February 9, 2012

The Food and Drug Administration on Wednesday issued a public warning that the use of proton-pump inhibitors or H2 blockers may be associated with an increased risk of Clostridium difficile‚Äďassociated diarrhea, or CDAD.

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday issued a public warning that the use of proton-pump inhibitors or H2 blockers may be associated with an increased risk of Clostridium difficile–associated diarrhea, or CDAD.

Patients should immediately contact their healthcare professional and seek care if they take PPIs and develop diarrhea that does not improve, the agency stated.

September 29, 2011

Costco Wholesale is calling on the farms that grow cantaloupes and the companies that ship them to be more vigilant in preventing contamination amid one of the deadliest outbreaks of foodborne disease in recent history, according to published reports.

NEW YORK — Costco Wholesale is calling on the farms that grow cantaloupes and the companies that ship them to be more vigilant in preventing contamination amid one of the deadliest outbreaks of foodborne disease in recent history, according to published reports.

September 14, 2011

A new resistant strain of methicillin-resistant staphylococcus aureus may be on the rise due to the frequent use of over-the-counter antibacterial ointments, according to a study to be published in the October issue of Emerging Infectious Diseases.

ATLANTA — A new resistant strain of methicillin-resistant staphylococcus aureus may be on the rise due to the frequent use of over-the-counter antibacterial ointments, according to a study to be published in the October issue of Emerging Infectious Diseases.

As reported by CNN.com, Japanese researchers made the finding after testing 259 MRSA strains for susceptibility to bacitracin and neomycin, two of the antibacterial ingredients commonly found in such OTC ointments as Neosporin and Polysporin.

May 31, 2011

The Food and Drug Administration has approved a treatment for diarrhea caused by a bacterial infection.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for diarrhea caused by a bacterial infection.

The agency announced the approval of Optimer Pharmaceuticals’ Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea, also known as CDAD.

January 24, 2011

The Food and Drug Administration has accepted a regulatory filing from Optimer Pharmaceuticals for a drug to treat bacterial infections.

SAN DIEGO — The Food and Drug Administration has accepted a regulatory filing from Optimer Pharmaceuticals for a drug to treat bacterial infections.

Optimer announced Monday the FDA’s acceptance of its approval application for fidaxomicin for treating clostridium difficile infection, or CDI. CDI is a colon infection that is a particular problem in hospitals, long-term care centers and in the broader community. It is estimated to affect more than 700,000 people per year. The agency has granted the application priority review and expects to finish its review by May 30.

November 8, 2010

A vaccine for a bacterial infection that affects the gastrointestinal tract has been granted expedited...

SWIFTWATER, Pa. A vaccine for a bacterial infection that affects the gastrointestinal tract has been granted expedited approval by the Food and Drug Administration.

 

French drug maker Sanofi-Aventis announced Tuesday that it had received fast-track designation from the FDA for its investigational Clostridium difficile vaccine. The FDA grants the designation to ease the development of new drugs and vaccines for serious or life-threatening conditions or unmet medical needs.